U.S. Markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.22
    +0.40 (+0.48%)
     
  • Gold

    1,818.20
    +1.70 (+0.09%)
     
  • Silver

    23.00
    +0.09 (+0.38%)
     
  • EUR/USD

    1.1409
    -0.0007 (-0.0570%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • Vix

    19.19
    -1.12 (-5.51%)
     
  • GBP/USD

    1.3644
    -0.0035 (-0.2592%)
     
  • USD/JPY

    114.6100
    +0.4100 (+0.3590%)
     
  • BTC-USD

    42,213.03
    -1,003.18 (-2.32%)
     
  • CMC Crypto 200

    1,001.89
    -23.84 (-2.32%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - November 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ: DRNA) stock prior to November 18, 2021.



You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dicerna to Novo Nordisk ("Novo). Under the terms of the merger Novo will initiate a tender offer to acquire all outstanding shares of Dicerna for $38.25 per share.

To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/dicerna-pharmaceuticals-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Dicerna merger investigation concerns whether the Board of Dicerna has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104252